Tag: trial

PARIS, July 07, 2025 (GLOBE NEWSWIRE) --  PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology, is pleased to announce that the first patient has been successfully dosed in its Phase I clinical trial (PST-611-CT1) aiming to assess safety and tolerability of its lead program, PST-611, in humans.

Webcast to be held Monday, July 7th at 8:00 a.m. ET

Platform Enhances Global Reach with Flexible Mining Plans, Referral Bonuses, and Industry-Leading Security

Washington, DC, July 06, 2025 (GLOBE NEWSWIRE) -- Research firm CryptoVision projects Solana (SOL) to revisit US $200-$220 and XRP to reclaim US $1.50-$1.80 before year-end. While most retail traders chase those targets with spot buys, MGPD Finance Limited, doing business as hashj cloud mining offers a smarter path: its new Turbo-Yield Dual-Engine Cloud Lane mines both assets in real time, turning price forecasts into compounding daily income. Every new registrant receives an $18 welcome credit plus $100 of free hash power—no hardware, no configuration, instant earnings.

The new platform eliminates the participation barrier, integrates AI intelligence and green energy, and makes remote mining a passive income channel accessible to everyone

The UK-based cloud mining platform now supports over 8.5 million users and strengthens its XRP offering with flexible, AI-optimized profit models

SAN DIEGO, July 05, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Sarepta Therapeutics, Inc. (NASDAQ; SRPT) securities between June 22, 2023 and June 24, 2025, inclusive (the “Class Period”), have until August 25, 2025 to seek appointment as lead plaintiff of the Sarepta class action lawsuit. Captioned Dolgicer v. Sarepta Therapeutics, Inc., No. 25-cv-05317 (S.D.N.Y.), the Sarepta class action lawsuit charges Sarepta as well as certain of Sarepta’s top executives with violations of the Securities Exchange Act of 1934.

NEW YORK, July 04, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sarepta Therapeutics, Inc. (“Sarepta” or “the Company”) (NASDAQ: SRPT) and certain of its officers.

Leonard Hill, Founder of Hill & Associates, Recognized for Outstanding Advocacy and Legal Excellence in Personal Injury Law.